Pembrolizumab (Keytruda®) with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction (GEJ) adenocarcinoma. Update July/August 2023

Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction (GEJ) adenocarcinoma. Update July/August 2023. Fact Sheet Nr. 145.

[thumbnail of Fact Sheet Nr.145_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
154kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 77 Psychopharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WI Digestive system > WI 250 Oesophagus WI Digestive system > WI 300-387 Stomach
Language:	English
Series Name:	Fact Sheet Nr. 145
Deposited on:	21 Aug 2023 14:51
Last Modified:	17 Nov 2023 15:41

Repository Staff Only: item control page